Phase II Trial of the Sigma-1 Receptor Agonist Cutamesine (SA4503) for Recovery Enhancement After Acute Ischemic Stroke

• Published in: Stroke (1970) Vol. 45; no. 11; pp. 3304 - 3310
• Main Authors: URFER, Roman, MOEBIUS, Hans J, SKOLOUDIK, David, SANTAMARINA, Estevo, SATO, Wakao, MITA, Shiro, MUIR, Keith W
• Format: Journal Article
• Language: English
• Published: Hagerstown, MD Lippincott Williams & Wilkins 01-11-2014
• Subjects: Adult; Aged; Aged, 80 and over; Biological and medical sciences; Brain Ischemia - diagnostic imaging; Brain Ischemia - physiopathology; Carbon Radioisotopes - pharmacology; Double-Blind Method; Female; Headache. Facial pains. Syncopes. Epilepsia. Intracranial hypertension. Brain oedema. Cerebral palsy; Humans; Internationality; Male; Medical sciences; Middle Aged; Nervous system (semeiology, syndromes); Neurology; Piperazines - pharmacology; Radionuclide Imaging; Receptors, sigma - agonists; Recovery of Function - physiology; Sigma-1 Receptor; Stroke - diagnostic imaging; Stroke - physiopathology; Time Factors; Vascular diseases and vascular malformations of the nervous system; clinical trial; Cerebral infarction; Stroke; Nervous system diseases; Sigma receptor; Cardiovascular disease; Cerebral disorder; randomized controlled trial; Vascular disease; Central nervous system disease; Phase II trial; Brain ischemia; SA 4503; Cerebrovascular disease; stroke
• ISSN: 0039-2499; 1524-4628
• DOI: 10.1161/strokeaha.114.005835

The σ-1 receptor (Sig-1R) agonist cutamesine (SA4503) enhanced functional recovery after experimental stroke with a treatment initiation window of 48 hours and chronic treatment for 28 days. We conducted a phase 2 clinical trial exploring the safety, tolerability, dose range, and functional effects of cutamesine in patients with ischemic stroke.
Subjects were randomized between 48 and 72 hours after stroke to receive cutamesine 1 mg/d, 3 mg/d, or placebo for 28 days. Effects on safety and function were assessed at baseline, at end of treatment (day 28), and at end of follow-up (day 56).
In 60 patients, treatment with both cutamesine dosages was safe and well tolerated without significant differences in numbers of treatment emergent or serious adverse events. No significant effect was observed on the primary efficacy measure (change in National Institutes of Health Stroke Scale from baseline to day 56) or modified Rankin Scale and Barthel Index scores. Post hoc analysis of moderately and severely affected patients (baseline National Institutes of Health Stroke Scale, ≥7 and ≥10) showed greater National Institutes of Health Stroke Scale improvements in the 3 mg/d cutamesine group when compared with placebo (P=0.034 and P=0.038, respectively). A trend toward a higher proportion being able to complete a 10m timed walk was observed for cutamesine-treated subjects.
Cutamesine was safe and well tolerated at both dosage levels. Although no significant effects on functional end points were seen in the population as a whole, greater improvement in National Institutes of Health Stroke Scale scores among patients with greater pretreatment deficits seen in post hoc analysis warrants further investigation. Additional studies should focus on the patient population with moderate-to-severe stroke.
http://www.clinicaltrials.gov/show/NCT00639249. Unique identifier: NCT00639249. The EudraCT number is 2007-004840-60 (https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-004840-60/GB).